Low-Dose Dextromethorphan, a NADPH Oxidase Inhibitor, Reduces Blood Pressure and Enhances Vascular Protection in Experimental Hypertension

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wu, Tao Cheng ^a,b   Chao, Chih Yu ^a   Lin, Shing Jong ^a,b   Chen, Jaw Wen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMLODIPINE; ANGIOTENSIN II; ANTIOXIDANT; DEXTROMETHORPHAN; NITRATE; NITRITE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PROTECTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CELL LINE; DEXTROMETHORPHAN; HEART RATE; HUMANS; HYPERTENSION; MALE; NADPH OXIDASE; RANDOM ALLOCATION; RATS; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES;

ANIMALIA; RATTUS;

EID: 84866705349     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046067     Document Type: Article

References (44)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, et al. (2005) Global burden of hypertension: Analysis of worldwide data. Lancet 365 (9455) ():: 217-223.
2. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS, (2007) Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 49 (1) ():: 69-75.
3. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, et al. (2002) Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 360 (9343) ():: 1347-1360.
4. O'Connor PJ, (2006) Improving medication adherence: Challenges for physicians, payers, and policy makers. Arch Intern Med 166 (17) ():: 1802-1804.
5. Hung CL, Liu CC, Yeh HI, Ko HJ, Hou CJY, et al. (2009) NT-ProBNP but not high sensitivity crp independently predict abnormal exercise duke score in well-controlled hypertension and pre-hypertension- An study from the subjects undergoing health evaluation. Acta Cardiol Sin 25 (1) ():: 7-17.
6. Mounier-Vehier C, Bernaud C, Carré A, Lequeuche B, Hotton JM, et al. (1998) Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. Am J Hypertens 11 (4 Pt 1) ():: 478-486.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (6) ():: 1206-1252.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (12) ():: 1462-1536.
9. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, et al. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350 (9080) ():: 757-764.
10. Liu L, Wang JG, Gong L, Liu G, Staessen JA, (1998) Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypergens 16 (12 Pt 1) ():: 1823-1829.
11. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, et al. (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 (9227) ():: 366-372.
12. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351 (9118) ():: 1755-1762.
13. The ALLAHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- LoweringTreatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (23) ():: 2981-2997.
14. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, et al. (2005) ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (9489) ():: 895-906.
15. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, et al. (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335 (15) ():: 1107-1114.
16. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, et al. (2004) VALUE trial group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 363 (9426) ():: 2022-2031.
17. Alvarez Y, Briones AM, Hernanz R, Pérez-Girón JV, Alonso MJ, et al. (2008) Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats. Br J Pharmacol 153 (5) ():: 926-935.
18. Tortella FC, Pellicano M, Bowery NG, (1989) Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 10 (12) ():: 501-507.
19. George CP, Goldberg MP, Choi DW, Steinberg GK, (1988) Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. Brain Res 440 (2) ():: 375-379.
20. Monyer H, Choi DW, (1988) Morphinans attenuate cortical neuronal injury induced by glucose deprivation in vitro. Brain Res 446 (1) ():: 144-148.
21. Prince DA, Feeser HR, (1988) Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia. Neurosci Lett 85 (3) ():: 291-296.
22. Steinberg GK, George CP, DeLaPaz R, Shibata DK, Gross T, (1988) Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke 19 (9) ():: 1112-1118.
23. Britton P, Lu XC, Laskosky MS, Tortella FC, (1997) Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. Life Sci 60 (20) ():: 1729-1740.
24. Tortella FC, Britton P, Williams A, Lu XC, Newman AH, (1999) Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 291 (1) ():: 399-408.
25. Zhang W, Wang T, Qin L, Gao HM, Wilson B, et al. (2004) Neuroprotective effect of DM in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 18 (3) ():: 589-591.
26. Chen JW, Chen YH, Lin FY, Chen YL, Lin SJ, (2003) Ginkgo biloba extract Inhibits tumor necrosis factor-α-induced reactive oxygen species generation, transcription factor activation, and cell adhesion molecule expression in human aortic endothelial cells. Arterioscler Thromb Vasc Biol 23 (9) ():: 1559-1566.
27. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, et al. (2003) Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52 (10) ():: 2603-2614.
28. Harrison DG, Gongora MC, Guzik TJ, Widder J, (2007) Oxidative stress and hypertension. J Am Soc Hypertens 1 (1) ():: 30-44.
29. Mullan BA, Young IS, Fee H, McCance DR, (2002) Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40 (6) ():: 804-809.
30. Widder JD, Guzik TJ, Mueller CF, Clempus RE, Schmidt HH, et al. (2007) Role of the multidrug resistance protein-1 in hypertension and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc Biol 27 (4) ():: 762-768.
31. Liu SL, Li YH, Shi GY, Tang SH, Jiang SJ, et al. (2009) Dextromethorphan reduce oxidative stress and inhibits atherosclerosis and neointima formation in mice. Cardiovas Res 82 (1) ():: 161-169.
32. Nishino T, Okamoto K, Eger BT, Pai EF, Nishino T, (2008) Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FASEBS J 275 (13) ():: 3278-3289.
33. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, et al. (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111 (8) ():: 1201-1209.
34. DeLano FA, Parks DA, Ruedi JM, Babior BM, Schmid-Schönbein GW, (2006) Microvascular display of xanthine oxidase and NADPH oxidase in the spontaneously hypertensive rat. Microcirculation 13 (7) ():: 551-566.
35. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, et al. (2006) Role of extracellular superoxide dismutase in hypertension. Hypertension 48 (3) ():: 473-481.
36. Lob HE, Vinh A, Li L, Blinder Y, Offermanns S, et al. (2011) Role of vascular extracellular superoxide dismutase in hypertension. Hypertension 58 (2) ():: 232-239.
37. Cai H, Harrison DG, (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (10) ():: 840-844.
38. Srivastava P, Hegde LG, Patnaik GK, Dikshit M, (1998) Role of endothelial-derived reactive oxygen species and nitric oxide in norepinephrine-induced rat aortic ring contractions. Pharmacol Res 38 (4) ():: 265-274.
39. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, et al. (2000) Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 101 (8) ():: 856-861.
40. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, et al. (2009) Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 30 (2) ():: 155-61.
41. Li F, Shi R, Liao M, Li J, Li S, et al. (2010) Losartan attenuates vascular remodeling of the aorta in spontaneously hypertensive rats and the underlying mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35 (8) ():: 807-13.
42. Bhatia K, Elmarakby AA, El-Remessy AB, Sullivan JC, (2012) Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 302 (2) ():: R274-82.
43. Fiese G, Perrin JH, (1969) Further investigations into the absorption of dextromethorphan from the rat's stomach. J Pharm Sci 58 (5) ():: 599-601.
44. Chen YW, Wang JJ, Liu TY, Chen YC, Hung CH, (2011) Systemic dextromethorphan and dextrorphan are less toxic in rats than bupivacaine at equiaesthetic doses. Can J Anaesth 58 (1) ():: 55-61.